Our Company has access to an impressive pipeline of technology opportunities originating from the Partners HealthCare research network as well as from a large number of Russian research institutions. To date Boston BioCom has initiated development of three specific programs. A fourth program, in central nervous system disease therapy, is under development.

Laser Immunomodulation Program: Applies novel insights on modification of the skin's immune system by non-destructive laser energy to create applications in vaccine adjuvants as well as direct immunotherapy. Read more..

New-Generation Antibody Program: Comprises several novel classes of monoclonal antibodies invented at the Massachusetts General Hospital and facilitated by a Russian technology platform. These antibodies are being developed mainly for oncology and infectious diseases. Read more..

Antibacterial Program: Focuses on generating new antibacterial drugs based on novel types of bacteriocins (naturally-developed defense systems of bacteria) that have been developed in Russia. Read more..

Most of these programs represent revolutionary, transformational approaches to the treatment of the diseases that they address. The figure below shows the prioritized technology programs by technology type and therapeutic focus.